JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Vor Biopharma (VOR – Research Report) today and set a price target of $6.00.
Silvan Tuerkcan’s rating is based on several promising developments at Vor Biopharma. The company is expected to release interim clinical updates for its lead programs, VCAR33 and trem-cel combined with Mylotarg, in 2025. These updates are anticipated to provide significant insights into the treatment benefits, particularly with a sufficient number of patients to assess the impact on relapse-free survival.
Additionally, Vor Biopharma’s financial position appears stable, with a year-end cash balance of $91.9 million and an operating expenditure that supports operations into the first quarter of 2026. The planned initiation of a Phase 1 clinical trial for the trem-cel and VCAR33 treatment system in the second half of 2025, along with previous encouraging data, suggests potential for improved responses. These factors contribute to Tuerkcan’s optimistic outlook and Buy rating for the stock.
In another report released on March 21, Wedbush also maintained a Buy rating on the stock with a $7.00 price target.